drugset / Trial / NCT00931125

Safety and Efficacy of Intravitreal Ranibizumab as a Preoperative Adjunct Treatment Before Vitrectomy Surgery in Proliferative Diabetic Retinopathy (PDR) Compared to Vitrectomy Alone

NCT00931125

Phase 2 Unknown 70 enrolled Attila Vajas Semmelweis University · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

This study investigates the hypothesis that ranibizumab injection given into the eye is a safe, efficacious and helping treatment option applied before surgical intervention of the proliferative diabetic retinal eye disorder.

Timeline

Start
2009-03
Primary completion
2013-09
Completion
2013-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Ranibizumab Monoclonal antibody 0.5 mg Intravitreal

Indications